Ann: Phase III Clinical Trial Update and New IIH Market Analysis, page-22

I am pretty confident that a very decent market remains for the drug for two reasons. The other GLP-1 agnostic do not lower ICP they just promote weight loss ,which can result in the alleviation of pressure symptoms for some but this is certainly not the case for everyone. Secondly about 15% to 20% of IIH suffers are not overweight when diagnosed. If they focused on this smaller market (those not overweight or who's issues are not resolved by weight loss) probably about 25% to 35% of the overall market, they should actually be able to charge a significantly higher price than has previously been contemplated.

They would need to figure out where the right balance between price and market but you would still be looking at annual revenue measured in the US$ 100s of million for IIH.